Clinical Trial Update: A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adalimumab for induction of clinical remission in Crohn's disease. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED